Daniel sent us this one — he wants to talk about gastric accommodation. How the stomach relaxes to make room for a meal in healthy people, what goes wrong when that reflex breaks down, especially after gallbladder surgery or with diabetes, and the treatment picture. Drugs that are repurposed or invented for it, plus practical tips, foods, drinks that might actually help. This one's right in your wheelhouse, Herman. Medicine, obscure reflexes, the gap between what textbooks say and what patients experience.
It really is. And you know what's striking? Most people have never heard the term "gastric accommodation." They know about acid reflux, they know about ulcers, but the idea that your stomach has to actively relax to receive food — that's not on anyone's radar until it stops working. Also, quick note — DeepSeek V four Pro is writing our script today.
So let's start with the basics before we get into what breaks. What's actually happening when a healthy person sits down to eat?
The stomach isn't just a passive bag. It's got two functionally distinct regions. The proximal stomach — that's the fundus and upper body — its job is to relax and hold food. The distal stomach, the lower part, grinds and empties. When you start eating, even before food hits your stomach, the act of chewing and swallowing triggers something called receptive relaxation. Then as food actually enters, there's adaptive relaxation. The fundus expands. A healthy stomach can go from about fifty milliliters at rest to holding roughly fifteen hundred milliliters without a meaningful rise in pressure.
Fifteen hundred milliliters. That's a liter and a half. A large soda bottle's worth.
And the key mediator here is nitric oxide. This is a vagally mediated reflex — the vagus nerve signals inhibitory neurons in the stomach wall that release nitric oxide, which relaxes the smooth muscle. If you block nitric oxide synthase, you reduce fundic relaxation. If you give nitrates, you increase postprandial gastric volume. There's a whole paper on this from the PMC archives that lays out the nitrergic pathway in detail.
It's an active, energy-requiring process. The stomach is choosing to relax.
And it's coordinated with what's happening downstream. There's this interesting dynamic where higher postprandial volume in the proximal stomach actually correlates with slower gastric emptying. The stomach is saying, "I've got a lot to process, let me hold onto this and meter it out slowly." Nutrients in the duodenum trigger cholecystokinin release, which feeds back and enhances the accommodation reflex. It's a beautifully tuned system.
Until it isn't. So let's talk about what happens when this goes haywire. Daniel mentioned two specific scenarios — after gallbladder surgery, and with diabetes. Start with the gallbladder one. That seems less obvious to me. You take out a gallbladder, why would your stomach forget how to relax?
This is genuinely understudied territory, and I want to be upfront about that. There are no direct studies that measure gastric accommodation before and after cholecystectomy. Nobody's put a barostat in someone, taken out their gallbladder, and measured again. But the symptom overlap is striking. There was a study in Frontiers in Medicine in twenty twenty-three that found new-onset functional dyspepsia in six point nine percent of patients one year after surgery. That's nearly one in fourteen people developing symptoms they didn't have before.
What kind of symptoms?
Early satiety, postprandial fullness, bloating, epigastric pain. The classic accommodation-failure profile. And there's a separate meta-analysis in Clinical Case Reports International that looked at bile reflux gastritis after cholecystectomy. When you lose the gallbladder, you lose the reservoir that stores and concentrates bile. Instead of a concentrated squirt when you eat a fatty meal, you get this continuous trickle of dilute bile into the duodenum. Some of it refluxes back into the stomach. Bile is alkaline and detergent-like — it disrupts the gastric mucosa, causes inflammation, and that inflammation may impair the accommodation reflex.
It's not that the surgery directly damages the vagus nerve or something. It's a downstream effect of altered bile flow.
That's the leading hypothesis. Although there's also a Journal of Neurogastroenterology and Motility paper from twenty fourteen reporting that about nineteen percent of patients have continuing or exacerbated dyspeptic symptoms after laparoscopic cholecystectomy. That's not a rounding error. And I think what's happening is that some of these patients had subclinical accommodation problems before surgery — maybe the gallbladder disease was masking it, or maybe the stress of surgery and the altered physiology tips them over the edge.
The nineteen percent figure is interesting because it suggests we're not just talking about a tiny minority who had a complicated surgery. This is a meaningful chunk of the millions of people who get their gallbladder out every year.
And here's the blind spot. When these patients go back to their surgeon or their gastroenterologist and say "I feel full after three bites, I'm bloated all the time," the workup usually looks for bile reflux, for retained stones, for sphincter of Oddi dysfunction. Nobody's measuring gastric accommodation. The test for it — a gastric barostat — is invasive, uncomfortable, and available in maybe a handful of research centers worldwide. So these patients get labeled as having "postcholecystectomy syndrome" or functional dyspepsia, and they're often told to just live with it.
The diagnostic gap is enormous. What about diabetes? That one seems more intuitive — nerve damage, gastroparesis, stomach doesn't empty. But accommodation is different from emptying, right?
Different mechanism, often coexisting. There's a key study from PubMed, the one that looked at visceral hypersensitivity and impaired accommodation in diabetic gastroparesis. What they found was nuanced. Diabetic patients showed significantly reduced accommodation response to liquid meals compared to healthy controls, even when their fasting gastric tone was normal. So the stomach isn't abnormally tight at rest — it just fails to relax when food arrives.
That's an important distinction. It's not that the stomach is always clenched.
And the causes are multifactorial. You've got autonomic neuropathy damaging the parasympathetic fibers of the vagus. You've got loss of the inhibitory neurons and the interstitial cells of Cajal in the stomach wall — these are the pacemaker cells that coordinate motility. And then there's a direct effect of high blood glucose itself, which impairs fundal tone. So it's nerve damage, structural changes in the stomach wall, and acute metabolic effects all piling on.
The blood glucose piece is interesting. That means even if you have the nerve damage, your symptoms could be worse on days when your sugar is poorly controlled.
And that study found that patients could have impaired accommodation alone, visceral hypersensitivity alone, or both. Visceral hypersensitivity means the stomach feels normal volumes as painful or uncomfortable. So two patients with identical accommodation measurements could have completely different symptom burdens depending on whether their nerves are amplifying the signal.
That complicates treatment enormously. If you don't know whether the problem is accommodation, hypersensitivity, or both, a drug that only fixes one mechanism might not help.
Which brings us to the drug landscape. Let me walk through what's available, what's been studied, and where the evidence is strong versus where it's shaky.
The best-studied repurposed drug is buspirone. You probably know it as an anti-anxiety medication.
The bus analogy, sure.
It's a five H T one A agonist. In the gut, activating those receptors enhances gastric accommodation. There was a randomized double-blind crossover trial by Tack and colleagues in twenty twelve — seventeen patients with functional dyspepsia, ten milligrams of buspirone three times daily. Gastric accommodation improved significantly. Two hundred twenty-nine milliliters versus one hundred forty-one milliliters with placebo. Overall dyspepsia symptom severity dropped from eleven point five to seven point five on their scale. P value under point zero zero five.
Seventeen patients is a tiny trial.
And that's where the evidence gets messy. A later -analysis in the Journal of Neurogastroenterology and Motility looked at the pooled data and found buspirone helped specifically with bloating, but didn't significantly improve overall functional dyspepsia symptoms compared to placebo. And the twenty twenty-five American Gastroenterological Association guideline for gastroparesis actually recommends against first-line use of buspirone.
The twenty twelve Tack trial says it works, the -analysis says maybe only for bloating, and the twenty twenty-five guideline says don't use it first-line. That's quite a spread.
Yet it's widely prescribed off-label for this exact purpose. The mechanism makes sense. The pilot data looked promising. But the high-quality evidence just isn't there for broad use. I think it's probably helpful for a subset of patients — the ones whose primary problem is impaired accommodation with bloating as their dominant symptom. But if you've got significant delayed emptying or predominant pain, buspirone might not do much.
What about drugs actually developed for this, not repurposed from psychiatry?
That's where acotiamide comes in. It's approved in Japan for functional dyspepsia with postprandial distress syndrome — which is basically the clinical correlate of impaired accommodation. It works by enhancing acetylcholine effects in the enteric nervous system, which improves both gastric accommodation and emptying. The phase three trial, a hundred milligrams three times daily, confirmed relief of postprandial fullness, bloating, and early satiety versus placebo.
It's not available in the US or Europe.
And this is one of those regulatory divergence stories that I find fascinating. Japan approved it based on their trials. The FDA and EMA haven't. It might be differences in regulatory standards, it might be questions about whether the efficacy generalizes across populations, it might be commercial strategy — the US functional dyspepsia market isn't exactly a blockbuster opportunity. But the bottom line is, American patients with impaired accommodation don't have access to the only drug specifically developed for their condition.
That's infuriating. What about the other drugs that get mentioned? I've seen sildenafil come up.
The sildenafil story is paradoxical and worth unpacking. In animal models, PDE five inhibitors looked promising for diabetic gastroparesis. The logic was that by preventing the breakdown of cyclic GMP, you'd enhance nitric oxide signaling, which would relax the pylorus and improve gastric emptying. So there was real mechanistic rationale.
Then they tested it in humans.
A controlled study in diabetic gastroparesis patients — fifty milligrams of sildenafil — found that it actually slowed gastric emptying. The half-emptying time increased from about one hundred sixty-three minutes to three hundred twenty-eight minutes. That's nearly doubling the time it takes to empty half the meal. And dyspepsia is among the most frequently reported adverse events for sildenafil.
A drug that relaxes smooth muscle made things worse. What's the explanation?
This is where the distinction between accommodation and emptying becomes crucial. Sildenafil probably does enhance fundic relaxation — one study in healthy volunteers showed it increased postprandial gastric volume by about fifty percent. But relaxing the fundus too much might actually impair the stomach's ability to generate the pressure gradients needed for emptying. Plus, it relaxes the lower esophageal sphincter, which can cause reflux. The net effect is that you feel full and bloated because your stomach is overly relaxed, and the food sits there longer. It's a perfect illustration of why impaired accommodation and delayed emptying are distinct problems that sometimes require opposite approaches.
You wouldn't give sildenafil to someone with accommodation problems.
You'd actively avoid it. And it's a cautionary tale about extrapolating from mechanism to clinical outcome without good trials. There are other drugs worth mentioning. Metoclopramide is the only FDA-approved drug for gastroparesis in the US, but it's a prokinetic — it speeds up emptying rather than specifically targeting accommodation. The twenty twenty-five AGA guideline recommends it as first-line pharmacotherapy for gastroparesis. But if your primary problem is impaired accommodation rather than delayed emptying, it might not address the root issue.
What about the older drugs?
Both five H T four agonists that enhance accommodation by acting on presynaptic receptors. Tegaserod at six milligrams twice daily increased pre and postprandial gastric volumes in healthy volunteers. But cisapride was withdrawn for cardiac safety — it caused QT prolongation and arrhythmias. Tegaserod has had a complicated regulatory history too, pulled and then partially reintroduced with restrictions. And nitric oxide donors like nitrates can enhance fundic relaxation, but they're short-acting and cause hypotension and headache. Not practical for chronic use.
The drug picture is buspirone with mixed evidence, acotiamide unavailable outside Japan, metoclopramide for a different problem, and a graveyard of drugs that either didn't work or weren't safe. What does that leave patients doing?
Diet and behavior become front-line therapy by default. And there's actually decent evidence for several approaches. The core principle is reducing the accommodation burden. Small, frequent meals — four to six per day — instead of three large ones. Your stomach doesn't have to relax as much for a three-hundred-calorie meal as for a nine-hundred-calorie one.
Makes intuitive sense. What about what you eat, not just when?
Low fat, low fiber, small particle foods. Fat delays gastric emptying and stimulates CCK, which in a normal stomach enhances accommodation, but in a dysfunctional stomach the signal might be distorted. The Cleveland Clinic's gastroparesis diet guidelines recommend keeping fat under forty to fifty grams per day. Lean meats, white rice, white bread, peeled or canned fruits, well-cooked vegetables, broth-based soups. Things that are easy to break down.
What to avoid?
High-fat fried foods, raw vegetables, whole grains, beans, nuts and seeds, carbonated beverages. Carbonation is interesting — you're introducing gas into a stomach that already can't accommodate properly. It's adding insult to injury.
I've also seen ginger mentioned.
Ginger has reasonable evidence for nausea, which often accompanies these conditions. Fennel for gas and bloating. Kiwi contains actinidin, a proteolytic enzyme that may improve gastric emptying and protein digestion. There's also amla fruit, used in Ayurvedic medicine, with some preliminary data. None of these are going to fix impaired accommodation, but they may help with the downstream symptoms.
Posture matters, right?
Sitting upright during and after meals, and gentle walking post-eating. Lying down after a meal when your stomach can't accommodate properly is asking for reflux and discomfort. There's a reason the advice is consistent across every gastroenterology clinic — it works.
Let me pull on a thread you mentioned earlier. The diagnostic gap. You said gastric barostat is invasive and rarely available. How do you actually diagnose impaired accommodation in practice?
In practice, you mostly don't. The gold standard is the barostat, which involves inserting a balloon into the stomach and measuring pressure-volume relationships. It's uncomfortable, time-consuming, and only available in research settings. There are non-invasive alternatives being developed — MRI-based volume measurements, SPECT imaging, ultrasound — but none have entered routine clinical use. So most gastroenterologists diagnose by symptom pattern and by excluding other causes. If a patient has early satiety, postprandial fullness, and bloating, and their gastric emptying study is normal, impaired accommodation is the presumptive diagnosis.
Which means a lot of patients are being treated empirically without ever knowing for sure what's wrong.
That's the reality. And the twenty twenty-five AGA guideline for gastroparesis recommends four-hour gastric emptying scintigraphy for solids as the diagnostic standard. But that tells you about emptying, not accommodation. You can have completely normal emptying and still have severe accommodation impairment. They're different tests for different problems, and the accommodation test barely exists outside of research.
We've got millions of people with post-cholecystectomy symptoms, millions more with diabetic gastroparesis, a diagnostic test that's essentially unavailable, and a treatment landscape where the best-studied drug has mixed evidence and the only purpose-built drug isn't approved in most of the world.
That's a fair summary. Though I want to add some nuance on the post-cholecystectomy piece. Not all of those nineteen percent with persistent symptoms have impaired accommodation. Some have bile reflux, some have retained stones, some have sphincter dysfunction, some probably had underlying functional dyspepsia that was misattributed to gallstones in the first place. Gallstones are common, functional dyspepsia is common — they coexist. Removing the gallbladder doesn't fix a stomach that was already dysfunctional.
That's an important point. The surgery might be a red herring in some cases, or it might unmask a pre-existing problem.
And that's why a careful pre-operative history matters. If someone has gallstones but their symptoms are atypical — more bloating and early satiety than episodic right upper quadrant pain after fatty meals — you might want to think twice about whether cholecystectomy will actually help.
Let's talk about the future. What's in the pipeline for impaired accommodation?
The most interesting area is probably the neurogastroenterology space more broadly. As we get better at understanding the enteric nervous system — it's sometimes called the second brain, and it has as many neurons as the spinal cord — we're identifying more specific drug targets. Acotiamide is a first-generation attempt at modulating acetylcholine in the gut. There will be more refined versions. There's also interest in ghrelin agonists. Ghrelin is the hunger hormone, and it has prokinetic effects. Relamorelin, a ghrelin agonist, has been studied for diabetic gastroparesis with some promise, though development has been stop-start.
The diagnostic side?
MRI is probably the most promising. You can measure gastric volume dynamically without radiation or invasive balloons. The challenge is cost and availability — you're not going to put every dyspepsia patient through a research-grade MRI protocol. But for difficult cases, it could become a clinical tool. There's also work on body surface gastric mapping — using electrodes on the skin to measure the stomach's electrical activity. It's non-invasive and could potentially distinguish between different motility disorders.
That sounds like an EKG for the stomach.
That's essentially what it is. And it's being developed in New Zealand, actually. Early data looks interesting, though it's not ready for prime time.
One thing I want to circle back to. You mentioned the buspirone trial showed benefit for bloating but not overall symptoms. For someone listening who has these symptoms — maybe after gallbladder surgery, maybe with diabetes — what should they actually ask their doctor about?
First, get the right diagnosis. Make sure you've had a gastric emptying study to rule out significant gastroparesis, and an upper endoscopy to rule out structural problems or bile reflux gastritis. Once those are done, if the symptom pattern fits impaired accommodation — early satiety, postprandial fullness, bloating — it's reasonable to discuss a trial of buspirone. It's generic, it's cheap, it's generally well-tolerated. The evidence isn't ironclad, but the risk-benefit ratio is favorable. Start low, ten milligrams before meals, and see if it helps.
If it doesn't?
Then you're in dietary management territory. Small frequent meals, low fat, low fiber. And if symptoms are severe and nothing else helps, some patients pursue acotiamide through international pharmacies, though that's obviously not something a doctor can formally recommend. There are also clinical trials — the gastroparesis clinical research network in the US runs studies periodically.
What about metoclopramide? You said it's first-line for gastroparesis per the guideline.
It's effective for emptying but comes with risks — tardive dyskinesia, a potentially irreversible movement disorder, with cumulative exposure. The FDA has a black box warning. So you don't want to use it casually, and you especially don't want to use it if the primary problem is accommodation rather than emptying. It might not help and it exposes the patient to real risk.
The treatment algorithm is: diagnose carefully, try buspirone if accommodation is the likely problem, lean heavily on diet, and reserve metoclopramide for confirmed delayed emptying.
That's where the evidence points. And I'd add: don't underestimate the dietary piece. The difference between three large meals and six small ones can be night and day for some patients. It's not glamorous, but it works.
Before we move to practical takeaways, I want to touch on something you mentioned about the US-Japan gap with acotiamide. Is this a common pattern? Drugs approved in Japan but not in the West for GI conditions?
It's not uncommon. Japan has a different regulatory framework and a different approach to functional GI disorders. They've been more willing to approve drugs based on symptom improvement in functional dyspepsia, whereas the FDA has historically wanted to see evidence of a clear mechanism and substantial efficacy. There's also a cultural difference — functional dyspepsia is recognized and diagnosed more readily in Japan, so the market is bigger, which incentivizes drug development. In the US, these patients often get bounced between primary care and GI without a clear label for what's wrong with them.
That fragmentation probably makes it harder to run trials and recruit patients.
If you don't have a clear diagnostic pathway and a concentrated patient population, clinical trials become much harder and more expensive. It's a structural problem in how we handle functional GI disorders in the West.
I think we've covered the physiology, the gallbladder and diabetes connections, the drug landscape, and the diagnostic gaps. Let's get practical.
Now: Hilbert's daily fun fact.
The average cumulus cloud weighs about one point one million pounds — roughly the same as eighty elephants floating overhead.
If you're dealing with early satiety, postprandial fullness, or bloating — whether after gallbladder surgery, with diabetes, or for unknown reasons — here's what to do. First, push for a proper workup. A gastric emptying study and an upper endoscopy at minimum. Don't accept "it's just indigestion" without those tests. Second, try the dietary modifications. Six small meals a day, low fat, low fiber, avoid carbonation. Give it two to three weeks before judging whether it helps. Third, if diet alone isn't enough, ask your gastroenterologist about a buspirone trial. It's off-label, but the evidence for bloating is reasonable and the safety profile is good. Fourth, if you're post-cholecystectomy and have persistent symptoms, ask specifically about bile reflux and whether a trial of a bile acid binder might be appropriate. That's a separate mechanism from accommodation, but it can produce overlapping symptoms.
One more thing. Keep a symptom diary. Note what you ate, when you ate it, and what symptoms you had and when. Patterns emerge that aren't obvious in the moment. You might find that your trigger is fat quantity, or meal volume, or eating too close to bedtime. That diary is more useful to your doctor than a vague report of "I feel bloated a lot.
The more specific you can be, the better the chance of matching treatment to mechanism.
The thing I keep coming back to is how invisible this problem is. You look fine, your endoscopy is normal, your emptying study might be normal, but you feel full after a few bites and bloated all afternoon. It's easy for doctors to dismiss, and it's easy for patients to think it's in their head. But it's not. It's a measurable, physiological defect. We just don't measure it very well.
And the fact that we have a drug in Japan specifically for this — acotiamide — and patients elsewhere can't get it, tells you something about how functional GI disorders are prioritized. We're not talking about a rare disease. Functional dyspepsia affects something like ten to fifteen percent of the population. Impaired accommodation is found in roughly forty percent of those patients. That's tens of millions of people worldwide.
The sildenafil story is a good cautionary note for anyone tempted to self-experiment based on mechanism. More relaxation isn't always better. The stomach needs to relax and then contract in a coordinated way. Breaking that coordination can make things worse.
I think the key insight from the research is that impaired accommodation and delayed emptying are distinct problems that sometimes travel together and sometimes don't. Treating the wrong one won't help and might harm. That's why diagnosis matters, even when the diagnostic tools are imperfect.
One open question I'm left with. You mentioned that no study has directly measured gastric accommodation before and after cholecystectomy. Given that millions of these surgeries happen every year, and up to nineteen percent of patients have persistent symptoms, that seems like a glaring research gap. Someone should do that study.
A prospective study with pre and post-operative accommodation measurement, plus symptom tracking, would answer a lot of questions. Is this pre-existing accommodation impairment that gets unmasked? Is it new impairment caused by altered bile flow? Is it a completely different mechanism that just looks like accommodation failure? We don't know. And until we do, we're treating empirically.
Which is where we are with a lot of functional GI disorders, unfortunately.
Progress is slow but real. Twenty years ago, nobody was talking about gastric accommodation outside of a few research labs. Now it's in the guidelines, there are drugs targeting it, and the diagnostic tools are improving. It's not fast enough for patients suffering today, but the trajectory is right.
Thanks to our producer Hilbert Flumingtop for keeping the show running. This has been My Weird Prompts. You can find every episode at myweirdprompts.I'm Corn.
I'm Herman Poppleberry. See you next time.
